cnot11 Antibody

What is CNOT11 and what cellular functions does it perform?

CNOT11 (CCR4-NOT transcription complex subunit 11) is a component of the CCR4-NOT complex, which plays important roles in mRNA deadenylation and transcriptional regulation. The protein is involved in post-transcriptional regulation of gene expression, particularly through modulating mRNA stability . Research has shown that the CCR4-NOT complex is critical for various cellular processes, including β-cell function in the pancreas, where dysregulation can contribute to diabetic phenotypes . The protein is found in both cytoplasmic and nuclear compartments, consistent with its dual roles in transcriptional and post-transcriptional regulation .

What applications are CNOT11 antibodies typically used for in research?

CNOT11 antibodies are primarily used for several key applications in molecular and cellular biology research:

These applications enable researchers to investigate CNOT11 expression patterns, subcellular localization, and protein-protein interactions in various experimental contexts .

How do I select the appropriate CNOT11 antibody for my research?

When selecting a CNOT11 antibody, consider these key factors:

• Target species compatibility: Verify the antibody has been validated for your species of interest (human, mouse, rat, etc.) through cross-reactivity testing .

• Application suitability: Ensure the antibody has been validated for your specific application (WB, IHC, IF, IP) with published validation data .

• Epitope recognition: Consider which region of CNOT11 the antibody recognizes. Some antibodies target specific domains (e.g., amino acids 264-314 as in some commercial antibodies), which may be important depending on your research questions .

• Clonality: Polyclonal antibodies offer broader epitope recognition but may have batch-to-batch variability, while monoclonal antibodies provide higher specificity for a single epitope .

• Validation methods: Look for antibodies validated through multiple techniques, including positive and negative controls, and those that have been verified in knockout/knockdown experiments .

What are the optimal protocols for using CNOT11 antibodies in Western blot applications?

For optimal Western blot results with CNOT11 antibodies:

• Sample preparation:

  • Use standard protein extraction buffers with protease inhibitors

  • For CNOT11 detection, load 20-30 μg of total protein per lane

  • Include positive control samples (e.g., HEK293 or HeLa cell lysates) where CNOT11 expression has been confirmed

• Gel electrophoresis and transfer:

  • Use 8-10% SDS-PAGE gels due to CNOT11's molecular weight

  • Transfer to PVDF or nitrocellulose membranes using standard protocols

• Antibody incubation:

  • Block membranes in 5% non-fat milk or BSA in TBST

  • Dilute primary CNOT11 antibody 1:500-1:2000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3-5 times with TBST

  • Incubate with appropriate secondary antibody (typically 1:5000-1:10000)

• Detection:

  • Expect to observe bands at the predicted molecular weight for CNOT11

  • Validate specificity using knockdown/knockout controls when possible

Note that the observed molecular weight may vary slightly from the calculated weight due to post-translational modifications or the presence of isoforms .

How should I optimize immunohistochemistry protocols for CNOT11 detection in tissue samples?

For successful immunohistochemical detection of CNOT11:

• Tissue preparation:

  • Fix tissues in 4% paraformaldehyde (PFA) for 24 hours at room temperature

  • Embed in paraffin and section at 3-5 μm thickness

  • For frozen sections, fix briefly in cold acetone or 4% PFA

• Antigen retrieval (critical step):

  • Perform heat-induced epitope retrieval using:
    a) 10 mM sodium citrate buffer (pH 6.0) at 120°C for 10 minutes in a pressure cooker , or
    b) TE buffer (pH 9.0) depending on the specific antibody recommendations

• Blocking and antibody incubation:

  • Block with 2% BSA in PBS with 0.05% Tween for 30-60 minutes

  • Dilute CNOT11 antibody 1:50-1:500 in blocking buffer

  • Incubate overnight at 4°C in a humidified chamber

  • Wash thoroughly with PBS-T

• Detection and visualization:

  • Use appropriate secondary antibody systems (HRP-conjugated or fluorophore-conjugated)

  • For chromogenic detection, develop with DAB substrate

  • For fluorescence, use compatible fluorophores and include DAPI nuclear counterstain

  • Mount with appropriate mounting medium

• Controls:

  • Always include positive control tissues known to express CNOT11

  • Include negative controls by omitting primary antibody or using tissues from knockdown/knockout models when available

What are the recommended approaches for RNA immunoprecipitation (RIP) using CNOT11 antibodies?

RNA immunoprecipitation (RIP) using CNOT11 antibodies can help identify RNA transcripts that interact with the CCR4-NOT complex. Based on published methodologies:

• Cell lysate preparation:

  • Harvest cells (e.g., MIN6 cell line for β-cell studies)

  • Lyse cells in non-denaturing lysis buffer containing RNase inhibitors

  • Clear lysates by centrifugation

• Immunoprecipitation:

  • Pre-clear lysates with protein A/G beads

  • Prepare antibody-bead complexes by incubating CNOT11 antibody with protein A/G beads

  • Include IgG control antibodies for negative control samples

  • Incubate lysates with antibody-bead complexes for 4 hours at 4°C

  • Wash beads extensively with wash buffers containing RNase inhibitors

• RNA extraction and analysis:

  • Extract RNA from immunoprecipitated samples and input controls

  • Perform reverse transcription followed by qPCR to detect specific transcripts

  • Calculate enrichment relative to input and IgG control samples

• Data interpretation:

  • Significant enrichment in CNOT11 IP compared to IgG control indicates association

  • For example, research has shown that specific mRNAs (like Slc16a1, Ldha, Cat) can be enriched in CNOT3 (another CCR4-NOT component) immunoprecipitated samples compared to IgG controls

  • Similar approaches can be applied to CNOT11 research

How can CNOT11 antibodies be used to investigate its role in the CCR4-NOT complex assembly and function?

CNOT11 antibodies can be leveraged for several advanced applications to study its role in CCR4-NOT complex assembly and function:

• Co-immunoprecipitation (Co-IP) studies:

  • Use CNOT11 antibodies to pull down the protein along with its interacting partners

  • Analyze by Western blot using antibodies against other CCR4-NOT components (e.g., CNOT1, CNOT3)

  • This approach can reveal which subunits directly interact with CNOT11 and how these interactions may be regulated under different conditions

• Proximity ligation assays (PLA):

  • Combine CNOT11 antibodies with antibodies against other complex components

  • Visualize and quantify protein-protein interactions in situ

  • Map spatial relationships within the complex at subcellular resolution

• ChIP-sequencing:

  • Use CNOT11 antibodies for chromatin immunoprecipitation followed by sequencing

  • Identify genomic regions where CNOT11 may be involved in transcriptional regulation

  • Compare with binding profiles of other CCR4-NOT components to understand cooperative functions

• Immunofluorescence co-localization:

  • Perform dual staining with CNOT11 and other CCR4-NOT component antibodies

  • Analyze subcellular localization patterns in different cell types or under various conditions

  • Quantify co-localization coefficients to assess complex integrity

These approaches can provide insights into how CNOT11 contributes to the structural organization and functional diversity of the CCR4-NOT complex in different cellular contexts.

What strategies can be employed to validate CNOT11 antibody specificity in research applications?

Rigorous validation of CNOT11 antibody specificity is critical for reliable research outcomes. Comprehensive validation strategies include:

• Genetic knockout/knockdown controls:

  • Use CRISPR/Cas9-mediated knockout cell lines or siRNA knockdown samples

  • Compare antibody signals between wild-type and CNOT11-depleted samples

  • Disappearance or significant reduction of signal in knockout/knockdown samples confirms specificity

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide

  • Apply this mixture in parallel with regular antibody applications

  • Specific signals should be blocked in the presence of the competing peptide

• Multi-antibody validation approach:

  • Use multiple antibodies targeting different epitopes of CNOT11

  • Compare detection patterns across applications

  • Consistent results with different antibodies increase confidence in specificity

• Orthogonal validation methods:

  • Correlate protein detection with mRNA expression (RT-qPCR)

  • Compare antibody-based detection with tagged overexpression systems

  • Analyze if antibody detects expected molecular weight proteins in Western blot

• Cross-reactivity assessment:

  • Test antibody performance across multiple species when working with model organisms

  • Confirm specificity in tissues/cells known to express varying levels of CNOT11

  • Document any cross-reactivity with highly homologous proteins

Implementing multiple validation approaches provides comprehensive evidence for antibody specificity and reliability in various research applications.

How can CNOT11 antibodies be utilized to investigate its role in mRNA deadenylation and decay pathways?

To investigate CNOT11's role in mRNA deadenylation and decay pathways:

• RNA stability assays with CNOT11 manipulation:

  • Perform CNOT11 knockdown/knockout in cellular models

  • Measure half-lives of candidate mRNAs using actinomycin D chase experiments

  • Compare mRNA decay rates between control and CNOT11-depleted conditions

  • Research with other CCR4-NOT components (e.g., CNOT3) has shown altered mRNA stability profiles following depletion

• Poly(A) tail length analysis:

  • Immunoprecipitate CNOT11 and associated mRNAs

  • Perform PAT (Poly(A) Tail) assays to measure poly(A) tail lengths

  • Compare tail lengths of CNOT11-bound vs. unbound mRNAs

  • Assess changes in poly(A) distribution following CNOT11 depletion

• RIP-seq to identify CNOT11-associated transcripts:

  • Perform RNA immunoprecipitation with CNOT11 antibodies followed by sequencing

  • Identify transcriptome-wide targets of CNOT11

  • Analyze sequence or structural motifs enriched in CNOT11-bound RNAs

  • Compare binding profiles with known deadenylation targets

  • Similar approaches with CNOT3 have identified specific mRNAs that interact with CCR4-NOT components

• Co-localization with P-bodies and stress granules:

  • Perform immunofluorescence to visualize CNOT11 along with markers of RNA decay compartments

  • Analyze dynamic recruitment to these structures under stress conditions

  • Correlate localization patterns with mRNA decay rates

• Tethering assays:

  • Tether CNOT11 to reporter mRNAs via MS2 or λN systems

  • Measure effects on reporter stability, translation, and poly(A) tail length

  • Determine which domains of CNOT11 are required for deadenylation activity

What are common challenges when using CNOT11 antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with CNOT11 antibodies. Here are common issues and their solutions:

• Weak or absent signal in Western blot:

  • Increase antibody concentration (try 1:250-1:500 if standard dilutions fail)

  • Extend primary antibody incubation time to overnight at 4°C

  • Use enhanced detection systems (e.g., higher sensitivity ECL reagents)

  • Optimize protein extraction methods to prevent degradation

  • Ensure transfer efficiency for high molecular weight proteins by using extended transfer times or lower percentage gels

• High background in immunostaining:

  • Increase blocking time and concentration (5% BSA instead of 2%)

  • Use more stringent washing steps (increase wash buffer volume and duration)

  • Titrate primary antibody to determine optimal concentration

  • Try alternative blocking reagents (normal serum from secondary antibody host species)

  • For tissues with high endogenous peroxidase activity, enhance quenching steps

• Non-specific bands in Western blot:

  • Use freshly prepared samples with protease inhibitors

  • Optimize antibody dilution and incubation conditions

  • Perform additional washing steps with higher stringency buffers

  • Consider using gradient gels for better separation

  • Compare observed banding patterns with predicted molecular weight (240-250 kDa for CNOT1)

• Inconsistent results between experiments:

  • Standardize protocols including sample preparation, antibody dilutions, and incubation times

  • Prepare larger batches of working dilutions to reduce variation

  • Include positive controls in each experiment

  • Document lot numbers of antibodies and verify consistency between batches

• Poor immunoprecipitation efficiency:

  • Pre-clear lysates thoroughly to reduce non-specific binding

  • Optimize antibody-to-bead ratios

  • Extend incubation time for antibody-antigen binding

  • Use gentler wash conditions to preserve interactions

  • Consider crosslinking antibodies to beads for cleaner results

How should CNOT11 antibodies be stored and handled to maintain optimal performance?

Proper storage and handling of CNOT11 antibodies is critical for maintaining their performance over time:

• Long-term storage recommendations:

  • Store antibodies at -20°C as recommended by manufacturers

  • Avoid repeated freeze-thaw cycles which can degrade antibody quality

  • Consider aliquoting antibodies into single-use volumes upon receipt

  • Monitor expiration dates and storage conditions regularly

• Working solution preparation:

  • Prepare fresh working dilutions for each experiment

  • Dilute in recommended buffers (typically PBS with 0.02% sodium azide and carrier protein)

  • For antibodies stored in glycerol formulations (e.g., 50% glycerol), allow to warm to room temperature before opening to prevent condensation

• Shipping and temporary storage:

  • Follow manufacturer guidelines for temporary storage if antibodies cannot be immediately stored at -20°C

  • Document receipt date and condition upon arrival

  • Avoid prolonged exposure to room temperature

• Contamination prevention:

  • Use sterile technique when handling antibody solutions

  • Never return unused antibody to the original stock

  • Use clean pipette tips for each handling

  • Check for visible signs of contamination or precipitation before use

• Performance monitoring:

  • Include positive controls in each experiment to verify antibody performance

  • Document lot numbers and compare results across different lots

  • Consider benchmarking new antibody lots against previous lots that performed well

Following these storage and handling practices helps ensure consistent antibody performance across experiments and maximizes the useful life of these valuable reagents.

What controls should be included when performing experiments with CNOT11 antibodies?

A robust experimental design with appropriate controls is essential when working with CNOT11 antibodies:

• Positive controls:

  • Include samples known to express CNOT11 (e.g., HEK293 cells, human brain tissue)

  • Use recombinant CNOT11 protein as a standard when available

  • Include tissues/cells where CNOT11 expression has been previously characterized

• Negative controls:

  • CNOT11 knockout or knockdown samples (critical for antibody validation)

  • Secondary antibody-only controls (omit primary antibody)

  • Isotype controls (non-specific IgG of the same species/isotype)

  • For IHC/IF, include tissues known not to express the target

• Specificity controls:

  • Peptide competition assays (pre-incubate antibody with immunizing peptide)

  • Multiple antibodies targeting different epitopes of CNOT11

  • Demonstrate signal reduction following RNA interference

• Procedural controls:

  • For co-immunoprecipitation: input samples, IgG pulldown controls

  • For RIP experiments: IgG control immunoprecipitations as demonstrated in studies of related proteins like CNOT3

  • For quantitative applications: loading controls (housekeeping proteins)

  • For immunostaining: autofluorescence controls, blocking peptide controls

• Cross-reactivity assessment:

  • Test antibody in samples from multiple species if cross-reactivity is claimed

  • Verify specificity in tissues with different expression levels

  • Validate using recombinant proteins of homologous family members

Including these controls allows for confident interpretation of results and helps troubleshoot any unexpected findings in CNOT11 research.

How can CNOT11 antibodies contribute to understanding its role in disease mechanisms?

CNOT11 antibodies can be powerful tools for investigating the protein's involvement in various disease mechanisms:

• Diabetes and metabolic disorders:

  • Research has shown that CCR4-NOT complex components like CNOT3 play critical roles in β-cell function and identity

  • CNOT11 antibodies can be used to examine expression patterns in diabetic vs. healthy pancreatic tissues

  • Immunohistochemical analysis can reveal changes in CNOT11 localization or expression levels in disease states

  • Co-localization studies with other β-cell markers can provide insights into potential dysfunction mechanisms

• Cancer biology:

  • Investigate CNOT11 expression patterns across different tumor types and stages

  • Correlate expression with clinical outcomes using tissue microarrays

  • Examine changes in subcellular localization that might indicate altered function

  • Study interactions with known oncogenes or tumor suppressors through co-immunoprecipitation

• Neurological disorders:

  • Analyze CNOT11 expression in brain tissues from patients with neurodegenerative diseases

  • Investigate potential role in RNA metabolism dysregulation, which is implicated in several neurological conditions

  • Examine co-localization with stress granules or other RNA processing bodies in disease models

• Research methodologies:

  • Combine CNOT11 antibody applications with patient-derived samples or disease models

  • Integrate with multi-omics approaches to correlate protein expression with transcriptomic and proteomic changes

  • Develop tissue and cell type-specific analysis workflows to identify context-dependent alterations

Understanding CNOT11's roles in disease mechanisms could potentially identify new therapeutic targets or biomarkers for conditions involving RNA metabolism dysregulation.

What are the considerations for using CNOT11 antibodies in single-cell analysis techniques?

As single-cell analysis technologies advance, researchers should consider these factors when incorporating CNOT11 antibodies:

• Single-cell immunofluorescence applications:

  • Optimize fixation and permeabilization protocols specific to CNOT11 detection

  • Validate antibody performance at the single-cell level before large-scale experiments

  • Consider automated imaging platforms with high-resolution capabilities

  • Implement quantitative image analysis workflows for objective assessment

• Mass cytometry (CyTOF) applications:

  • Metal-conjugate CNOT11 antibodies following validated protocols

  • Verify epitope accessibility after conjugation

  • Optimize antibody concentration for sufficient signal without spillover

  • Include appropriate controls for batch normalization

• Single-cell Western blot considerations:

  • Adjust lysis conditions to efficiently extract CNOT11 from individual cells

  • Optimize protein capture and separation parameters

  • Validate detection sensitivity at the single-cell level

  • Consider microfluidic platforms designed for low-abundance proteins

• Spatial proteomics applications:

  • Evaluate compatibility with multiplexed immunofluorescence approaches

  • Optimize signal amplification methods for low-abundance detection

  • Validate specificity in tissue contexts with appropriate controls

  • Consider cyclic immunofluorescence methods for co-detection with multiple markers

• Data analysis considerations:

  • Develop analysis pipelines that account for cell-to-cell variability

  • Implement clustering approaches to identify distinct expression patterns

  • Correlate CNOT11 expression with cellular phenotypes and functional states

  • Consider integration with single-cell transcriptomics data

These considerations will help researchers effectively incorporate CNOT11 antibodies into emerging single-cell analysis platforms, enabling new insights into cellular heterogeneity in normal and disease states.

How might CNOT11 antibodies be used in combination with other molecular tools to advance our understanding of RNA regulation?

Integrating CNOT11 antibodies with complementary molecular tools creates powerful research approaches:

• Combination with CRISPR-based technologies:

  • Use CNOT11 antibodies to validate knockouts/knockins generated by CRISPR-Cas9

  • Combine with CRISPRi/CRISPRa to correlate protein levels with phenotypic changes

  • Implement CRISPR screens followed by CNOT11 immunoprecipitation to identify functional interactions

  • Develop CRISPR-based tagging approaches that can be detected with existing antibodies

• Integration with RNA-protein interaction methods:

  • Combine CNOT11 RIP with high-throughput sequencing (RIP-seq)

  • Implement CLIP (Cross-Linking Immunoprecipitation) using CNOT11 antibodies to map direct RNA binding sites

  • Correlate binding profiles with RNA stability measurements

  • Study shared and distinct RNA targets across CCR4-NOT complex components

  • Previous studies with related components like CNOT3 have successfully identified RNA targets using immunoprecipitation approaches

• Multi-omics integration:

  • Correlate CNOT11 protein levels/localization with transcriptome-wide changes

  • Combine proteomics of CNOT11 interactome with transcriptomics of affected mRNAs

  • Integrate with genome-wide approaches (ChIP-seq, ATAC-seq) to understand transcriptional impacts

  • Develop computational frameworks to model CNOT11's role in RNA regulation networks

• Live-cell imaging approaches:

  • Use nanobodies derived from CNOT11 antibodies for live-cell applications

  • Implement split fluorescent protein systems to visualize dynamic interactions

  • Correlate spatiotemporal dynamics with RNA fate in real-time

  • Study assembly/disassembly of CCR4-NOT complexes under various conditions

• Therapeutic development applications:

  • Use antibodies to validate targets in therapeutic screening pipelines

  • Develop methods to modulate CNOT11 function in disease models

  • Implement antibody-based proximity labeling to identify novel therapeutic targets

  • Validate on-target effects of emerging RNA-targeted therapeutics

These integrated approaches combine the specificity of CNOT11 antibodies with complementary technologies to build comprehensive understanding of RNA regulatory mechanisms in normal physiology and disease.